Ted R. Mikuls

Active 2000–2025

163
Papers
18,887
Citations
76
h-index
151
i10-index

Citations

Citations per year for Ted R. Mikuls2000: 1 citations2001: 2 citations2002: 11 citations2003: 24 citations2004: 27 citations2005: 32 citations2006: 41 citations2007: 53 citations2008: 75 citations2009: 98 citations2010: 132 citations2011: 139 citations2012: 154 citations2013: 157 citations2014: 157 citations2015: 152 citations2016: 154 citations2017: 128 citations2018: 129 citations2019: 448 citations2020: 568 citations2021: 692 citations2022: 753 citations2023: 523 citations2024: 944 citations2025: 391 citations2026: 11 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,904 citing papers, 22.2% of this breakdownChina: 685 citing papers, 8% of this breakdownUnited Kingdom: 635 citing papers, 7.4% of this breakdownItaly: 415 citing papers, 4.9% of this breakdownCanada: 363 citing papers, 4.2% of this breakdownGermany: 354 citing papers, 4.1% of this breakdownFrance: 336 citing papers, 3.9% of this breakdownNetherlands: 283 citing papers, 3.3% of this breakdownJapan: 252 citing papers, 3% of this breakdownSweden: 252 citing papers, 2.9% of this breakdownSpain: 240 citing papers, 2.8% of this breakdownAustralia: 224 citing papers, 2.6% of this breakdown
0%22.2%Other 30.7%

Fields

  • Medicine78.8%
  • Biochemistry, Genetics and Molecular Biology8.9%
  • Immunology and Microbiology5.7%
  • Dentistry2%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Neuroscience0.5%
  • Other3.4%

Topics

  • Rheumatoid Arthritis Research and Therapies14.7%
  • Gout, Hyperuricemia, Uric Acid5.1%
  • Systemic Lupus Erythematosus Research4.5%
  • Spondyloarthritis Studies and Treatments3.8%
  • Autoimmune and Inflammatory Disorders Research2.7%
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis2.1%
  • Other67.1%

Coauthors

All papers

Open in search
  1. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2022 cited by 1,705

  2. 2020 American College of Rheumatology Guideline for the Management of Gout

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linan Zeng, Mary Ann Zhang, Amy S. Turner, Tuhina Neogi - Arthritis & Rheumatology 2020 cited by 955

  3. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications

    Authors: , , , - BMJ 2018 cited by 609

  4. 2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures

    Authors: , , , , , , , , , , - Arthritis Care & Research 2019 cited by 281

  5. Periodontitis and Porphyromonas gingivalis in Patients With Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2014 cited by 376

  6. Comparative Effectiveness of Allopurinol and Febuxostat in Gout Management

    Authors: , , , , , , , , , , , , , , , , - NEJM Evidence 2022 cited by 100

  7. The impact of disease severity measures on survival in U.S. veterans with rheumatoid arthritis-associated interstitial lung disease

    Authors: , , , , , , , , , , , , , , - Lara D. Veeken 2022 cited by 55

  8. Validation of the Rheumatic Disease Comorbidity Index

    Authors: , , , , - Arthritis Care & Research 2014 cited by 277

  9. Association of Antibodies to Prevotella copri in Anti–Cyclic Citrullinated Peptide‐Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2022 cited by 33

  10. Rheumatoid Factor as a Potentiator of Anti–Citrullinated Protein Antibody–Mediated Inflammation in Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , , - Arthritis & Rheumatology 2014 cited by 238

  11. Gout

    Authors: - New England Journal of Medicine 2022 cited by 70

  12. Malondialdehyde‐Acetaldehyde Adducts and Anti–Malondialdehyde‐Acetaldehyde Antibodies in Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2014 cited by 152

  13. American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5

    Authors: , , , , , , , , , , , , , - Arthritis & Rheumatology 2022 cited by 114

  14. Autoantibody Seropositivity and Risk for Interstitial Lung Disease in a Prospective Male-Predominant Rheumatoid Arthritis Cohort of U.S. Veterans

    Authors: , , , , , , , , , , - Annals of the American Thoracic Society 2020 cited by 60

  15. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study

    Authors: , , , , , , - RMD Open 2019 cited by 156

  16. Malondialdehyde–Acetaldehyde Adducts and Antibody Responses in Rheumatoid Arthritis–Associated Interstitial Lung Disease

    Authors: , , , , , , , , , , , , - Arthritis & Rheumatology 2019 cited by 84

  17. Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , , - Arthritis & Rheumatology 2019 cited by 81

  18. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis

    Authors: , , , , , , , , , , - Annals of the Rheumatic Diseases 2021 cited by 47

  19. Porphyromonas gingivalis and disease‐related autoantibodies in individuals at increased risk of rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , - Arthritis & Rheumatism 2012 cited by 225

  20. Heightened immune response to autocitrullinated Porphyromonas gingivalis peptidylarginine deiminase: a potential mechanism for breaching immunologic tolerance in rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , - Annals of the Rheumatic Diseases 2013 cited by 199

  21. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis

    Authors: , , , , , , , , - Seminars in Arthritis and Rheumatism 2019 cited by 83

  22. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis

    Authors: , , , , , , , , , , , , , , , , , , , , , - Arthritis Care & Research 2008 cited by 1,491

  23. Cause‐Specific Mortality in Male US Veterans With Rheumatoid Arthritis

    Authors: , , , , , , , , , , , , - Arthritis Care & Research 2015 cited by 151

  24. Comparative Profiling of Serum Protein Biomarkers in Rheumatoid Arthritis–Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis

    Authors: , , , , , , , , , , , , , , , , - Arthritis & Rheumatology 2019 cited by 63